Post by: Colleen Parr Dekker
- First Quarter 2024 Financial Results
- Revenue of $1,205 million
- Reported Net income of $32 million, Adjusted Net income of $167 million
- Adjusted EBITDA of $294 million, or 24.4% of Revenue
- Reported EPS of $0.06, Adjusted EPS of $0.34
- Net leverage ratio of 6.1x Adjusted EBITDA
- Year over year growth rates are meaningfully impacted by a shift in customer purchasing related to the ERP Blackout in 2023, with an estimated $90 to $110 million of revenue shift from the second quarter of 2023 into the first quarter of 2023
- Updating full year 2024 financial guidance to reflect first quarter outperformance offset by expected unfavorable impact of foreign exchange rates:
- Revenue of $4,460 to $4,515 million, constant currency growth improves to 2% to 3%
- Reported Net Loss of $(3) to $(45) million; Reported EPS of $(0.01) to $(0.09)
- Adjusted EBITDA of $960 to $1,000 million; Adjusted EPS of $0.88 to $0.96
GREENFIELD, Ind (May 8, 2024) - Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the first quarter of 2024, provided guidance for the second quarter of 2024, and updated guidance for the full year 2024.
